Clinical Trials Logo

Clinical Trial Summary

Cognitive impairment is independently related to low birth weight, low birth length and small head circumference. SGA children who have not experienced height and / or head circumference catch-up have the worst cognitive function. The serum IGF-1 level of short SGA children is significantly lower than that of catch-up SGA children. This may be due to the defect of GH-IGF-1 axis, resulting in some hGH / IGF-1 deficiency. GH treatment can induce catch-up growth of head circumference, especially for those with small birth head circumference, growth hormone can help to improve IQ, behavior and self cognition of children with SGA. Two years after birth is the most critical period for children's physical, neurological, cognitive and emotional development. This study evaluated the effect of growth hormone treatment on the improvement of cognitive function and growth and development of symmetrical SGA children who did not show catch-up growth from 6 months to 2 years old. This is an innovative study. The minimum age of previous similar studies is 19 months. The starting age of this study is 6 months, and the results are to improve the cognitive development of SGA infants. This is the first of its kind. Although the safety of growth hormone in SGA infants younger than 2 years old has not been reported, it is based on a number of studies on the application of growth hormone in infants, such as PWS and GHD, It can be expected that there will be no short-term and long-term adverse reactions. The study was conducted in 17 hospitals led by Tongji Hospital Affiliated to Tongji Medical College of Huazhong University of science and technology


Clinical Trial Description

Subjects: SGA children from 6 months to 2 years old who meet the enrollment conditions shall be informed of the enrollment by the researcher and the subject's guardian, and the subject's guardian shall decide to participate in the test drug group or the control group. GH treatment group (n = 68): the subjects were given PEG-rhGH injection 0.2 mg / kg / week (initial dose), once a week, subcutaneously before going to bed for 104 weeks. Each follow-up, the researchers adjusted the dosage according to the IGF-1 results of the center and other individual conditions. Control group (n = 68): no treatment, only follow-up examination and growth and development related evaluation, and the follow-up time was 104 Week. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05144035
Study type Interventional
Source Tongji Hospital
Contact Xiaoping Luo, director
Phone 13387522645
Email xpluo@tjh.tjmu.edu.cn
Status Recruiting
Phase Phase 4
Start date April 6, 2022
Completion date June 30, 2026

See also
  Status Clinical Trial Phase
Completed NCT02987868 - Effects of an Amino Acid-Based hGH Secretagogue on Triiodythyronine N/A
Recruiting NCT03431727 - Acromegaly - Before and After Treatment
Completed NCT03038594 - Growth Hormone Therapy for Muscle Regeneration in Severely Burned Patients Phase 2/Phase 3
Completed NCT03203356 - Adrenal Function in GHD Children N/A
Completed NCT02782221 - Lipolytic Effects of GH in Human Subjects in Vivo N/A
Completed NCT05195437 - Evolution of the Quality of Life of Short Statured Children Treated With Growth Hormone : Evaluation at Adult Size
Completed NCT05105685 - Effectiveness of Recombinant Human Growth Hormone Therapy for Children With PMS Phase 1/Phase 2
Completed NCT04244123 - Web-based Adherence Information Integrated Nurse-led Monitoring Clinic
Not yet recruiting NCT03005561 - Detection of Difficulties and Improvement Compliance to Growth Hormone Treatment N/A
Recruiting NCT06448195 - Effects of Growth Hormone Therapy on Metabolic Function in Fatty Liver Post-Pituitary Adenoma Surgery Phase 4
Completed NCT03033121 - Three-times-weekly Versus Daily Growth Hormone (GH) Treatment in naïve GH-deficient Children Phase 3
Not yet recruiting NCT05660356 - Growth Hormone Deficiency in Mild Traumatic Brain Injury Early Phase 1
Active, not recruiting NCT00867971 - Is Recombinant Growth Hormone Therapy Associated With Increased Intraoccular Pressure? N/A
Recruiting NCT05253287 - Growth Hormone in Decompensated Liver Cirrhosis Phase 2/Phase 3
Active, not recruiting NCT03091374 - Impact of Recombinant Human Growth Hormone on HIV Persistence Phase 2
Not yet recruiting NCT02326610 - Early hGH Treatment of SGA Infants to Prevent Irreversible Neurologic and Psychological Damage and Sequelae Phase 2
Recruiting NCT06103513 - Randomized Clinical Trial of Two Different Initial Growth Hormone Doses in Children Phase 3
Recruiting NCT04938466 - Assessment of Adherence, Quality of Life, Clinical Response and Safety of Daily and Long-Acting Growth Hormone Therapy
Recruiting NCT06037473 - The Efficacy and Safety of PEGylated GH for the Treatment of Short Stature in Chinese Children-GLOBE Reg
Recruiting NCT03878992 - Effects of Growth Hormone and IGF-1 on Anabolic Signals and Stem Cell Recruitment in Human Skeletal Muscle N/A